Showing results (41-50 of 48) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
BMC Cancer|December 18, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancerP Lebok, V Kopperschmidt, M Kluth, et al.Cancer Biology & Therapy|May 12, 2015
8p deletion is strongly linked to poor prognosis in breast cancerP Lebok, A Mittenzwei, M Kluth, et al.Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.Gynecologic Oncology|October 13, 2021
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancerG E Konecny, A E Wahner Hendrickson, T M Davidson, et al.British Journal of Cancer|January 7, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT studyF Trillsch, S Mahner, E Vettorazzi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT studyF Trillsch, S Mahner, L Woelber, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJ A Ledermann, X Matias-Guiu, F Amant, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2020
Prognostic gene expression signature for high-grade serous ovarian cancerJ Millstein, T Budden, E L Goode, et al.Pageof 5